Poor test results for Roche cloud growth prospects

ZURICH (Reuters) - A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings.